FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

GLOBAL HEALTH Previous Volume 360:1063-1065 March 12, 2009 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

In 2006, the results of pivotal clinical trials of two new rotavirus vaccines — RotaTeq (Merck) and Rotarix (GlaxoSmithKline) — were published, and high efficacy (85 to 98%) against severe rotavirus diarrhea was reported for both products.^1,2 Perhaps even more important, neither vaccine was associated with intussusception, an adverse effect that had led to the withdrawal of another rotavirus vaccine — RotaShield, made by Wyeth–Lederle — from the U.S. market in 1999. The rapid resurgence of rotavirus vaccines after the abrupt and devastating setback associated with the withdrawal of RotaShield was remarkable, reflecting the commitment of the public health community . . . [Full Text of this Article]

Source Information

Dr. Parashar leads the Viral Gastroenteritis Epidemiology Team in the Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta. Dr. Glass is the director of the Fogarty International Center, National Institutes of Health, Bethesda, MD.

This article has been cited by other articles:

• Danchin, M. H., Bines, J. E. (2009). Defeating Rotavirus? The Global Recommendation for Rotavirus Vaccination. NEJM 361: 1919-1921 [Full Text]